Avita Medical, Inc. - Common Stock — 분기별 재무 통계 (NASDAQ:RCEL)

Financials

영업활동으로 인한 현금 -8.08 M-10.31 M-10.23 M-5.22 M-5.44 M-10.07 M -30.96 M 투자 활동으로 인한 현금 2.47 M10.77 M7.02 M-5.34 M11 K2.04 M 3.73 M 재무활동으로 인한 현금 1.02 M363 K559 K13.77 M248 K6.1 M 20.67 M 잉여 현금 흐름 -8.08 M-10.31 M-10.75 M-6.17 M-4.83 M-10.09 M -31.85 M

Avita Medical, Inc. - Common Stock

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa and Australia.

RCEL

Financials

Avita Medical, Inc. - Common Stock

뉴스

AVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue Growth Transcript

AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript

Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?

AVITA Medical: Why The BARDA Rally Changes Nothing (NASDAQ:RCEL)

아비타 메디컬, TD 코웬 컨퍼런스 참가: 성장과 전략적 집중

Avita Medical at TD Cowen Conference: Growth and Strategic Focus

Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade

Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know

AVITA Medical, Inc. (RCEL) Discusses Financial Performance, Sales Strategy, and Reimbursement Progress Transcript

AVITA Medical, Inc. (RCEL) Q4 2025 Earnings Call Transcript

아비타 메디컬, 2026년 12~19% 성장 목표…2025년 4분기 실적 발표

Avita Medical Q4 2025 slides: 11% annual growth with 12-19% expansion targeted for 2026